journal article·2026-05-27

Simple Surface Charge Engineering of Conjugated Polymer Nanoparticles for Potent Dual-Mode Photoinactivation of Resistant Bacteria and Biofilms

Arianna L. Sosa-Lochedino, Sol R. Martínez, Emmanuel Odella, Virginia Aiassa, Matías Caverzan, Luis E. Ibarra, Carlos A. Chesta, Rodrigo E. Palacios

ACS Applied Materials & Interfaces· Volume 18· Issue 20
Publisher page

Abstract

The emergence of antibiotic-resistant bacteria, particularly in biofilm-associated infections, poses a severe threat to global health. Light-activated therapies, such as photodynamic inactivation (PDI) and photothermal therapy (PTT), offer promising alternatives. This study describes a straightforward self-assembly approach for producing positively charged core/shell conjugated polymer nanoparticles ( F8BT-PtOEP@PFN NPs ) to improve the effectiveness of antimicrobial phototherapy. The core consists of poly(9,9-dioctylfluorene- alt -benzothiadiazole) ( F8BT ) doped with the photosensitizer platinum(II) octaethylporphyrin ( PtOEP ), while the shell is made up of a cationic polyfluorene derivative ( PFN ). These nanoparticles exhibit a remarkable combination of a suitable singlet oxygen quantum yield (Φ Δ = 0.23), an outstanding photothermal conversion efficiency (η = 0.95), and excellent photostability. The cationic PFN shell dramatically enhances electrostatic binding to methicillin-resistant Staphylococcus aureus (MRSA, a Gram-positive bacterium), as confirmed by flow cytometry and supported by comparative ζ-potential measurements of bacteria before and after NP incubation. In planktonic cultures, F8BT-PtOEP@PFN NPs exhibited a bactericidal effect under blue light, achieving a >4 log reduction in colony-forming units, whereas the uncoated (anionic) NPs ( F8BT-PtOEP NPs ) only had a bacteriostatic effect. More importantly, the core/shell NPs were highly effective against mature MRSA biofilms, significantly reducing biomass, metabolic activity, and exopolysaccharide matrix integrity, as demonstrated by crystal violet, MTT, and calcofluor white assays, respectively. The core/shell NPs also exhibited excellent biocompatibility with eukaryotic cells. This study highlights the profound impact of simple surface engineering on the effectiveness of conjugated polymer nanoparticles in potent PDI–PTT against resilient bacterial biofilms. To our knowledge, these combined features (cationic conjugated polymer NPs with a Φ Δ of 0.23 and an η of 0.95 for dual PDI–PTT action) have not previously been achieved simultaneously in a single nanoparticle system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Antimicrobial agents and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados (IITEMA)

Universidad Nacional de Río Cuarto (UNRC), Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET)

Departamento de Química. Facultad de Ciencias Exactas

Fisicoquímicas y Naturales, UNRC

UNITEFA-CONICET, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas

Universidad Nacional de Córdoba

Departamento de Patología Animal, Facultad de Agronomía y Veterinaria

Universidad Nacional de Río Cuarto

Instituto de Biotecnología Ambiental y Salud (INBIAS), UNRC y CONICET

Departamento de Biología Molecular. Facultad de Ciencias Exactas

Funding

Secretaría de Ciencia y Técnica, Universidad Nacional de Río Cuarto · Consejo Nacional de Investigaciones Científicas y Técnicas · Agencia Nacional de Promoción Científica y Tecnológica

References (73)

Show source-provided references
1. 10.3390/antibiotics1001000310.3390/antibiotics10010003 ↗
2. 10.1016/j.ijantimicag.2009.12.01110.1016/j.ijantimicag.2009.12.011 ↗
3. 10.1038/nrmicro241510.1038/nrmicro2415 ↗
4. 10.1038/nrmicro.2016.9410.1038/nrmicro.2016.94 ↗
5. Raab O. · Z. Biol. · 1900 · 39 · 524
6. 10.1039/b311900a10.1039/b311900a ↗
7. 10.4155/fmc.09.5510.4155/fmc.09.55 ↗
8. 10.3390/pharmaceutics1410205010.3390/pharmaceutics14102050 ↗
9. 10.1111/bjd.1209810.1111/bjd.12098 ↗
10. 10.26717/BJSTR.2018.06.00137710.26717/BJSTR.2018.06.001377 ↗
11. 10.1016/j.ijantimicag.2017.11.00310.1016/j.ijantimicag.2017.11.003 ↗
12. 10.3389/fmicb.2022.102099510.3389/fmicb.2022.1020995 ↗
13. 10.3389/fchem.2019.0082410.3389/fchem.2019.00824 ↗
14. 10.3389/fmicb.2020.56632510.3389/fmicb.2020.566325 ↗
15. 10.1586/14787210.2013.81186110.1586/14787210.2013.811861 ↗
16. 10.2147/IJN.S12195610.2147/IJN.S121956 ↗
17. 10.1039/C6RA07480D10.1039/C6RA07480D ↗
18. 10.3390/app903040110.3390/app9030401 ↗
19. 10.1039/D4NR04593A10.1039/D4NR04593A ↗
20. 10.1016/j.dyepig.2017.09.04410.1016/j.dyepig.2017.09.044 ↗
21. 10.1016/j.drudis.2023.10349310.1016/j.drudis.2023.103493 ↗
22. 10.1021/acs.jpcc.1c0720810.1021/acs.jpcc.1c07208 ↗
23. 10.1038/aps.2017.4210.1038/aps.2017.42 ↗
24. 10.3390/pharmaceutics1504111610.3390/pharmaceutics15041116 ↗
25. 10.1002/smo.2022001010.1002/smo.20220010 ↗
26. 10.3390/nano1006112310.3390/nano10061123 ↗
27. 10.1039/C9NR01833F10.1039/C9NR01833F ↗
28. 10.1021/acsami.3c0055610.1021/acsami.3c00556 ↗
29. 10.1039/D1TC03128G10.1039/D1TC03128G ↗
30. 10.1002/marc.20190060110.1002/marc.201900601 ↗
31. 10.1016/j.bioadv.2023.21339910.1016/j.bioadv.2023.213399 ↗
32. 10.1021/acs.macromol.3c0202610.1021/acs.macromol.3c02026 ↗
33. 10.1039/D4MH01802H10.1039/D4MH01802H ↗
34. 10.1016/j.bioadv.2024.21415810.1016/j.bioadv.2024.214158 ↗
35. 10.1021/acsinfecdis.0c0026810.1021/acsinfecdis.0c00268 ↗
36. 10.1016/j.jphotobiol.2024.11297110.1016/j.jphotobiol.2024.112971 ↗
37. 10.2217/nnm-2017-029210.2217/nnm-2017-0292 ↗
38. 10.1117/12.252676310.1117/12.2526763 ↗
39. 10.1016/j.jphotobiol.2020.11204510.1016/j.jphotobiol.2020.112045 ↗
40. 10.2217/nnm-2020-010610.2217/nnm-2020-0106 ↗
41. Ibarra L. E. · 2020
42. 10.3390/pharmaceutics1308125810.3390/pharmaceutics13081258 ↗
43. 10.3390/pharmaceutics1403062610.3390/pharmaceutics14030626 ↗
44. 10.3390/cells1211154110.3390/cells12111541 ↗
45. 10.3390/pharmaceutics1705059310.3390/pharmaceutics17050593 ↗
46. 10.1021/am302910q10.1021/am302910q ↗
47. 10.1016/j.colsurfb.2014.10.04310.1016/j.colsurfb.2014.10.043 ↗
48. 10.1021/acs.chemmater.5c0122410.1021/acs.chemmater.5c01224 ↗
49. 10.1016/j.ultras.2023.10718010.1016/j.ultras.2023.107180 ↗
50. 10.1021/j100168a01510.1021/j100168a015 ↗
51. 10.1002/mabi.20190030110.1002/mabi.201900301 ↗
52. 10.1128/JB.184.2.547-555.200210.1128/JB.184.2.547-555.2002 ↗
53. 10.1016/j.dyepig.2017.07.04210.1016/j.dyepig.2017.07.042 ↗
54. 10.1007/s43630-023-00503-410.1007/s43630-023-00503-4 ↗
55. 10.1021/jacs.8b0501410.1021/jacs.8b05014 ↗
56. 10.1016/S1473-3099(16)30268-710.1016/S1473-3099(16)30268-7 ↗
57. 10.1128/jcm.01934-1710.1128/jcm.01934-17 ↗
58. Naghili H. · Vet. Res. Forum · 2013 · 4 · 179
59. 10.1021/acsomega.4c0116810.1021/acsomega.4c01168 ↗
60. 10.1128/JB.186.3.722-729.200410.1128/JB.186.3.722-729.2004 ↗
61. Agarwal A. · Indian J. Med. Res. · 2013 · 138 · 262
62. 10.1088/2050-6120/aa640510.1088/2050-6120/aa6405 ↗
63. 10.1016/0003-2697(76)90527-310.1016/0003-2697(76)90527-3 ↗
64. 10.1002/anie.20100426010.1002/anie.201004260 ↗
65. 10.3390/nano1309154310.3390/nano13091543 ↗
66. 10.1073/pnas.76.12.604710.1073/pnas.76.12.6047 ↗
67. 10.1016/j.jphotobiol.2022.11251010.1016/j.jphotobiol.2022.112510 ↗
68. 10.1021/acsapm.0c0071110.1021/acsapm.0c00711 ↗
69. 10.1038/nrmicro186110.1038/nrmicro1861 ↗
70. 10.1146/annurev-micro-092412-15562010.1146/annurev-micro-092412-155620 ↗
71. 10.1016/j.bbamem.2021.18359710.1016/j.bbamem.2021.183597 ↗
72. 10.3390/polym303119910.3390/polym3031199 ↗
73. 10.1021/la304488910.1021/la3044889 ↗